一种新的成像剂检测出高精度的转移性三联负乳腺癌,超过标准的PET扫描,特别是在大脑中,并显示出未来定向治疗的前景。 A new imaging agent detected metastatic triple negative breast cancer with high accuracy, outperforming standard PET scans, especially in the brain, and showing promise for future targeted treatments.

名为OPALESCECT的第二阶段试验发现,TLX250-CDx(一种针对碳氢化合物九的PET/CT成像剂)有效检测到转移性三联负乳腺癌,总体敏感度为87.5%,包括乳房、皮肤和肾上腺损伤的100%敏感度,在确定脑转移方面超过FDG PET/CT标准。 A Phase 2 trial called OPALESCENCE found that TLX250-CDx, a PET/CT imaging agent targeting carbonic anhydrase IX, effectively detected metastatic triple negative breast cancer with 87.5% overall sensitivity, including 100% sensitivity in breast, skin, and adrenal lesions, and outperformed standard FDG PET/CT in identifying brain metastases. 它还显示淋巴结和骨头的检测率很高,肿瘤体积测量相仿,没有安全问题。 It also showed high detection rates in lymph nodes and bone, with comparable tumor volume measurements and no safety concerns. 其结果证明它有可能诊断具有侵略性、缺氧驱动的肿瘤,并推进未来使用放射性同位素进行疗养治疗,尽管该物剂仍然在调查和未经批准。 The results support its potential for diagnosing aggressive, hypoxia-driven tumors and advancing future theranostic treatments using radioactive isotopes, though the agent remains investigational and unapproved.